text:
Teva Reports First Quarter 2022 Financial Results
Revenues of $3.7 billion
GAAP diluted loss per share of $0.86
Non-GAAP diluted EPS of $0.55
Cash flow used in operating activities of $49 million
Free cash flow of $117 million
2022 revenue outlook revised lower to reflect ongoing impact of foreign exchange fluctuations; COPAXONE® outlook revised lower mainly to reflect increased competition and foreign exchange fluctuations; all other key components reaffirmed:
Revenues of $15.4 - $16.0 billion vs. previous range of $15.6 - $16.2 billion
COPAXONE revenues of approximately $750 million vs. previous outlook of approximately $850 million
Adjusted EBITDA of $4.7 - $5.0 billion
Non-GAAP diluted EPS of $2.40 - $2.60
Free cash flow of $1.9 - $2.2 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2022.
Mr. Kåre Schultz, Teva's President and CEO, said, 2022 is off to a solid start with the successful launch of a first generic version of Revlimid® in the United States, and gains in market share for AJOVY® both in the United States and in Europe, where it has solidified its leadership position as the second leading brand. AUSTEDO® continues to grow as more patients with tardive dyskinesia are being diagnosed and are receiving treatment. We are also pleased to continue resolving opioid-related litigations with recent settlements in Florida and Rhode Island including the provision of lifesaving opioid treatments and recovery medicines for those who need them."
Mr. Schultz continued: "While easing of COVID-19 related restrictions has led to positive momentum in our European business, we are seeing fluctuations of foreign exchange rates, and have therefore lowered our 2022 revenue outlook, while reaffirming our earnings and cash flow guidance."
First Quarter 2022 Consolidated Results
Revenues in the first quarter of 2022 were $3,661 million, a decrease of 8%, or 5% in local currency terms, compared to the first quarter of 2021. This decrease was mainly due to lower revenues in our North America segment primarily related to generic products and COPAXONE, partially offset by higher revenues from Anda and generic products in our Europe segment.
Exchange rate movements during the first quarter of 2022, including hedging effects, negatively impacted our revenues by $133 million and our GAAP and non-GAAP operating income by $56 million and $59 million, respectively.
GAAP gross profit was $1,740 million in the first quarter of 2022, a decrease of 7% compared to the first quarter of 2021. GAAP gross profit margin was 47.5% in the first quarter of 2022, compared to 47.2% in the first quarter of 2021. The increase in gross profit margin was mainly driven by our network consolidation activities, as well as a change in product portfolio mix in our International Markets segment, partially offset by the unfavorable mix of generic products in our North America segment and lower revenues from COPAXONE. Non-GAAP gross profit was $1,986 million in the first quarter of 2022, a decrease of 7% compared to the first quarter of 2021. Non-GAAP gross profit margin was 54.2% in the first quarter of 2022, compared to 53.8% in the first quarter of 2021.
GAAP Research and Development (R&D)expenses in the first quarter of 2022 were $225 million, a decrease of 11% compared to the first quarter of 2021. Non-GAAP R&D expenses were $221 million, or 6.0% of quarterly revenues, in the first quarter of 2022, compared to $244 million, or 6.1%, in the first quarter of 2021. In the first quarter of 2022, our R&D expenses related primarily to specialty product candidates in neuroscience (such as migraine, movement disorders/ neurodegeneration and neuropsychiatry, including post-approval commitments), immunology (such as respiratory medicines) and selected other areas, as well as generic products including biosimilars. Our lower R&D expenses in the first quarter of 2022, compared to the first quarter of 2021, were mainly due to a decrease in neuroscience (in the pain and migraine and headache therapeutic areas), as well as various generics projects.
GAAP Selling and Marketing (S&M)expenses in the first quarter of 2022 were $584 million, flat compared to the first quarter of 2021. Non-GAAP S&M expenses were $552 million, or 15.1% of quarterly revenues, in the first quarter of 2022, compared to $549 million, or 13.8%, in the first quarter of 2021.
GAAP General and Administrative (G&A) expenses in the first quarter of 2022 were $296 million, an increase of 2% compared to the first quarter of 2021. Non-GAAP G&A expenses were $252 million, or 6.9% of quarterly revenues, in the first quarter of 2022, compared to $278 million, or 7%, in the first quarter of 2021.
GAAP other income and Non-GAAP other income in the first quarter of 2022 was $52 million, compared to $5 million in the first quarter of 2021. Other income in the first quarter of 2022 was mainly the result of settlement proceeds in our International Markets segment.
GAAP operating loss in the first quarter of 2022 was $713 million, compared to operating income of $434 million in the first quarter of 2021. GAAP operating loss in the first quarter of 2022 was mainly affected by legal settlements and loss contingencies, primarily related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. Non-GAAP operating income in the first quarter of 2022 was $1,013 million, a decrease of 6%, compared to $1,077 million in the first quarter of 2021. This decrease in non-GAAP operating income was mainly due to lower profit in our North America segment, partially offset by higher profit in our Europe and International Markets segments. Non-GAAP operating margin was 27.7% in the first quarter of 2022, compared to 27.1% in the first quarter of 2021.
EBITDA (defined as operating income (loss), excluding amortization and depreciation expenses) was negative $390 million in the first quarter of 2022, compared to EBITDA of $809 million in the first quarter of 2021. Adjusted EBITDA (defined as non-GAAP operating income excluding depreciation expenses) was $1,135 million in the first quarter of 2022, a decrease of 6% compared to $1,206 million in the first quarter of 2021.
GAAP financial expenses, net were $258 million in the first quarter of 2022, compared to $290 million in the first quarter of 2021. Financial expenses in the first quarter of 2022, were mainly comprised of interest expenses of $238 million. Financial expenses in the first quarter of 2021 were mainly comprised of interest expenses of $239 million and loss on revaluations of marketable securities of $64 million. Non-GAAP financial expenses, net were $247 million in the first quarter of 2022, compared to $227 million in the first quarter of 2021.
In the first quarter of 2022, we recognized a GAAP tax expense of $2 million, on pre-tax loss of $971 million. In the first quarter of 2021, we recognized a tax expense of $62 million, on pre-tax income of $144 million. Our tax rate for the first quarter of 2022 was mainly affected by legal settlement charges and interest expense disallowances. Non-GAAP income taxes in the first quarter of 2022 were $142 million, or 18.5%, on pre-tax non-GAAP income of $766 million. Non-GAAP incometaxes in the first quarter of 2021 were $146 million, or 17%, on pre-tax non-GAAP income of $851 million. Our non-GAAP tax rate in the first quarter of 2022 was mainly affected by the mix of products we sold and interest expense disallowances.
We expect our annual non-GAAP tax rate for 2022 to be 18%-19%, unchanged from our outlook provided in February 2022.
GAAP net loss attributable to Teva and GAAP diluted loss per share were $955 million and $0.86, respectively, in the first quarter of 2022, compared to net income of $77 million and diluted earnings per share of $0.07 in the first quarter of 2021. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per sharein the first quarter of 2022 were $609 million and $0.55, respectively, compared to $699 million and $0.63 in the first quarter of 2021.
The weighted averagediluted shares outstanding used for the fully diluted share calculation for the three months ended March 31, 2022 and 2021 was 1,107 million shares. The weighted average diluted shares outstanding used for the fully diluted share calculation on a non-GAAP basis for the three months ended March 31, 2022 and 2021 was 1,112 million and 1,107 million shares, respectively.
As of March 31, 2022 and 2021, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,145 million and 1,130 million, respectively.
Non-GAAP information: Net non-GAAP adjustments in the first quarter of 2022 were $1,564 million. Non-GAAP net income and non-GAAP EPS for the first quarter of 2022 were adjusted to exclude the following items:
Legal settlements and loss contingencies of $1,124 million;
Amortization of purchased intangible assets of $200 million, of which $178 million is included in cost of sales and the remaining $22 million in S&M expenses;
Impairment of long-lived assets of $165 million, comprised mainly of impairment of intangible assets of product rights assets in connection with the Actavis Generics acquisition;
Contingent consideration expense of $33 million, mainly related to an increase in future royalties;
Finance expenses of $11 million;
Other items of $91 million; and
Income tax of $140 million.
Teva believes that excluding such items facilitates investors' understanding of its business.
Commencing in the first quarter of 2022, we no longer exclude IPR&D acquired in development arrangements from our non-GAAP financial measures. In our comparable non-GAAP financial measures for the first quarter of 2021, we excluded $5 million IPR&D acquired in development arrangements. We are not recasting the non-GAAP presentation for the first quarter of 2021 since the adjustment is not significant. We are making this change to our presentation of non-GAAP financial measures to improve comparability of our non-GAAP presentation to those of other companies in the pharmaceutical industry that are making a similar change to their presentations beginning in the first quarter of 2022.
For further information, see the tables below for a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and the information under "Non-GAAP Financial Measures." Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow used in operating activities during the first quarter of 2022 was $49 million, compared to $405 million in the first quarter of 2021. The lower cash flow used in operating activities in the first quarter of 2022 was mainly due to changes in working capital items resulting from a decrease in accounts receivables net of SR&A in connection with the decrease in revenues.
Free cash flow (defined as cash flow used in operating activities, cash used for capital investments, beneficial interest collected in exchange for securitized accounts receivables, proceeds from divestitures of businesses and other assets and cash used for acquisition of businesses, net of cash acquired) was $117 million in the first quarter of 2022, compared to $59 million in the first quarter of 2021. The increase in the first quarter of 2022 resulted mainly from lower cash flow used in operating activities, partially offset by lower sales of assets.
As of March 31, 2022, our debt was $22,917 million, compared to $23,043 million as of December 31, 2021. This decrease was mainly due to exchange rate fluctuations. Our debt as of March 31, 2022 was effectively denominated in the following currencies: 61% in U.S. dollars, 36% in euros and 3% in Swiss francs. The portion of total debt classified as short-term as of March 31, 2022 was 9%, compared to 6% as of December 31, 2022. Our financial leverage was 69% as of March 31, 2022, compared to 67% as of December 31, 2021. Our average debt maturity was approximately 6.2 years as of March 31, 2022, compared to 6.4 years as of December 31, 2021.
In April 2022, we entered into an unsecured syndicated sustainability-linked revolving credit facility ("RCF") of $1.8 billion with a maturity date of April 2026, with two one-year extension options, which replaces Teva's existing revolving credit facility. The RCF is linked to two sustainability performance targets. The RCF margin may increase or decrease depending on the Company's sustainability performance.
Segment Results for the First Quarter of 2022
The following table presents revenues, expenses and profit for our North America segment for the three months ended March 31, 2022 and 2021:
Revenues from our North America segment in the first quarter of 2022 were $1,737 million, a decrease of $251 million, or 13%, compared to the first quarter of 2021, mainly due to a decrease in revenues from generic products and COPAXONE, partially offset by higher revenues from ANDA.
Revenues in the United States, our largest market, were $1,638 million in the first quarter of 2022, a decrease of $216 million or 12% compared to the first quarter of 2021.
The following table presents revenues for our North America segment by major products and activities for the three months ended March 31, 2022 and 2021:
BENDEKA®/TREANDA®
Generic products revenues in our North America segment (including biosimilars) in the first quarter of 2022 were $899 million, a decrease of 15% compared to the first quarter of 2021, mainly due to increased competition on key products and lower volumes, partially offset by higher revenues from lenalidomide capsules (the generic version of Revlimid®) and Truxima®.
In the first quarter of 2022, our total prescriptions were approximately 302 million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions according to IQVIA data.
On March 7, 2022 we announced the launch of the first generic version of Revlimid® (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States. These lenalidomide capsules are a prescription medicine used in adults for the treatment of (i) multiple myeloma in combination with the medicine dexamethasone, (ii) certain myelodysplastic syndromes, and (iii) mantle cell lymphoma following specific prior treatment.
AJOVY revenues in our North America segment in the first quarter of 2022 increased by 16% to $36 million, compared to the first quarter of 2021, mainly due to growth in volume.
AUSTEDO revenues in our North America segment in the first quarter of 2022 increased by 6%, to $154 million, compared to $146 million in the first quarter of 2021, mainly due to growth in volume.
BENDEKA and TREANDA combined revenues in our North America segment in the first quarter of 2022 decreased by 10% to $82 million, compared to the first quarter of 2021, mainly due to the availability of alternative therapies and continued competition from Belrapzo® (a ready-to-dilute bendamustine hydrochloride product from Eagle).
COPAXONE revenues in our North America segment in the first quarter of 2022 decreased by 48% to $86 million, compared to the first quarter of 2021, mainly due to generic competition in the United States and a decrease in glatiramer acetate market share due to availability of alternative therapies.
Anda revenues in our North America segment in the first quarter of 2022 increased by 18% to $342 million, compared to $289 million in the first quarter of 2021, mainly due to higher demand for COVID-related products.
Gross profit from our North America segment in the first quarter of 2022 was $890 million, a decrease of 17%, compared to $1,074 million in the first quarter of 2021. This decrease was mainly due to lower gross profit from generic products and lower gross profit from COPAXONE.
Gross profit margin for our North America segment in the first quarter of 2022 decreased to 51.2%, compared to 54.0% in the first quarter of 2021. This decrease was mainly due to a change in the mix of generic products and COPAXONE.
Profit from our North America segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our North America segment in the first quarter of 2022 was $402 million, a decrease of 30% compared to $577 million in the first quarter of 2021, mainly due to lower revenues, as discussed above.
Our Europe segment includes the European Union, the United Kingdom and certain other European countries.
The following table presents revenues, expenses and profit for our Europe segment for the three months ended March 31, 2022 and 2021:
§ Represents an amount less than $0.5 million or 0.5%, as applicable.
Revenues from our Europe segment in the first quarter of 2022 were $1,156 million, a decrease of 5%, or $58 million, compared to the first quarter of 2021. In local currency terms, revenues increased by 3%. In the first quarter of 2021, our lower revenues were impacted by the implications of the COVID-19 pandemic. In the first quarter of 2022, our higher revenues were attributed to higher demand for generic and OTC products resulting mainly from the removal of restrictions related to doctor and hospital visits by patients that were previously implemented in response to the COVID-19 pandemic, as well as higher sales of cough and cold products. In the first quarter of 2022, revenues were negatively impacted by exchange rate fluctuations of $67 million, net of hedging effects.
The following table presents revenues for our Europe segment by major products and activities for the three months ended March 31, 2022 and 2021:
Generic products revenues in our Europe segment in the first quarter of 2022, including OTC products, increased by 1% to $876 million, compared to the first quarter of 2021. In local currency terms, revenues increased by 8%, mainly due to higher demand for generic and OTC products, resulting mainly from the removal of restrictions related to doctor and hospital visits by patients that were previously implemented in response to the COVID-19 pandemic, as well as higher sale of cough and cold products.
AJOVY revenues in our Europe segment in the first quarter of 2022 increased to $30 million, compared to $16 million in the first quarter of 2021, mainly due to growth in European countries in which AJOVY had previously been launched, as well as launches and reimbursements in additional European countries.
COPAXONE revenues in our Europe segment in the first quarter of 2022 decreased by 29% to $72 million, compared to the first quarter of 2021. In local currency terms, revenues decreased by 24%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products.
Respiratory products revenues in our Europe segment in the first quarter of 2022 decreased by 24% to $71 million compared to the first quarter of 2021. In local currency terms, revenues decreased by 19%, mainly due to price reductions.
Gross profit from our Europe segment in the first quarter of 2022 was $694 million, an increase of 1% compared to $688 million in the first quarter of 2021.
Gross profit margin for our Europe segment in the first quarter of 2022 increased to 60.0%, compared to 56.6% in the first quarter of 2021. This increase was mainly due to lower cost of goods sold, mainly driven by our network consolidation activities, as well as a decrease in write-offs.
Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our Europe segment in the first quarter of 2022 was $381 million, an increase of 13%, compared to $338 million in the first quarter of 2021. This increase was mainly due to higher gross profit and reduced expenses, as discussed above.
Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. The key markets in this segment are Japan, Russia and Israel.
On February 1, 2021, we completed the sale of the majority of the generic and operational assets of our business venture in Japan.
In February 2022, Russia launched an invasion of Ukraine. As of the date of this press release, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results. We have no manufacturing or R&D facilities in these markets. During the first quarter of 2022, the impact of this conflict on our International Markets segment results of operations and financial condition was immaterial.
The following table presents revenues, expenses and profit for our International Markets segment for the three months ended March 31, 2022 and 2021:
Revenues from our International Markets segment in the first quarter of 2022 were $492 million, flat compared to the first quarter of 2021. In local currency terms, revenues increased by 8% compared to the first quarter of 2021, mainly due to higher revenues in certain markets, partially offset by lower revenues in Japan resulting from the divestment mentioned above, as well as regulatory price reductions and generic competition to off-patented products. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns.
The following table presents revenues for our International Markets segment by major products and activities for the three months ended March 31, 2022 and 2021:
Generic products revenues in our International Markets segment in the first quarter of 2022, which include OTC products, decreased by 1% in U.S. dollar. In local currency terms, revenues increased by 9% to $388 million, compared to the first quarter of 2021. This increase was mainly due to higher revenues in certain markets, partially offset by lower sales in Japan resulting from the divestment mentioned above, as well as regulatory price reductions and generic competition to off-patented products in Japan.
AJOVY was launched in certain markets in our International Markets segment, including Japan in August 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the first quarter of 2022 were $6 million, compared to $1 million in the first quarter of 2021.
COPAXONE revenues in our International Markets segment in the first quarter of 2022 were $10 million, compared to $12 million in the first quarter of 2021.
AUSTEDO waslaunched in early 2021 in China for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia and was also launched in Israel during 2021. In October 2021, we received marketing approval for both indications in Brazil. We continue with additional submissions in various other markets.
Gross profit from our International Markets segment in the first quarter of 2022 was $286 million, an increase of 10% compared to $260 million in the first quarter of 2021.
Gross profit margin for our International Markets segment in the first quarter of 2022 increased to 58.1%, compared to 53.0% in the first quarter of 2021. This increase was mainly due to a change in product portfolio mix, price increases largely as a result of rising costs due to inflationary pressure and a positive impact from hedging activity, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.
Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our International Markets segment in the first quarter of 2022 was $179 million, an increase of 47%, compared to $122 million in the first quarter of 2021. This increase was mainly due to higher gross profit as well as other income.
We have other sources of revenues, primarily the sale of active pharmaceutical ingredients ("APIs") to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above.
Our revenues from other activities in the first quarter of 2022 were $275 million, a decrease of 5% compared to the first quarter of 2021. In local currency terms, revenues were flat.
API sales to third parties in the first quarter of 2022 were $181 million, an increase of 2% in both U.S. dollars and local currency terms, compared to the first quarter of 2021.
$ billions, except EPS
May 2022 Outlook
February 2022 Outlook
2021 Actual
COPAXONE ($m)
AUSTEDO ($m)
AJOVY ($m)
EPS ($)
1,114 million shares
Non-GAAP Tax Rate
Teva will host a conference call and live webcast including a slide presentation on Tuesday, May 3, 2022, at 8:00 a.m. ET to discuss its first quarter 2022 results and overall business environment. A question & answer session will follow.
In order to participate, please dial the following numbers:
United States: 1 (877) 870-9135
International: +44 (0) 2071 928338
Israel: 1 (809) 213-985
A live webcast of the call will be available on Teva's website at: ir.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website or by calling the following numbers: United States 1-866-331-1332; International +44 (0) 3333 009785; passcode: 8636304.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.
Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.
This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP EPS, non-GAAP operating income, non-GAAP gross profit, non-GAAP gross profit margin, EBITDA, Adjusted EBITDA, non-GAAP R&D expenses, non-GAAP S&M expenses, non-GAAP G&A expenses, non-GAAP financial expenses, non-GAAP income taxes, non-GAAP income (loss) before income taxes, non-GAAP tax rate, non-GAAP net income (loss), non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS are presented in order to facilitates investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance, in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management's annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP figures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing forward looking guidance for GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort.
our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO, AJOVY and COPAXONE; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic;
the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; environmental risks; and the impact of ESG issues;
other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities (including as a result of potential tax reform in the United States); and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Intangible assets impairments
Financial expenses, net
Income (loss) before income taxes
Income taxes (benefit)
Share in (profits) losses of associated companies, net
Net income (loss) attributable to non-controlling interests
Earnings (loss) per share attributable to Teva: Basic ($)
Non-GAAP net income attributable to Teva:*
Non-GAAP net income attributable to Teva for diluted earnings per share:
Non-GAAP earnings per share attributable to Teva:* Basic ($)
Accounts receivables, net of allowance for credit losses of $91
million and $90 million as of March 31, 2022 and December 31,
Accounts payables
Net income (loss) $
Impairment of long-lived assets and assets held for sale
Net loss (gain) from investments and from sale of long lived assets
Net cash provided by (used in) operating activities
Beneficial interest collected in exchange for securitized accounts receivables
Proceeds from sale of business and long-lived assets
Acquisition of businesses, net of cash acquired
Proceeds from sale of investments
Redemption of convertible senior notes
Net change in cash, cash equivalents and restricted cash
Balance of cash, cash equivalents and restricted cash at beginning of period
Balance of cash, cash equivalents and restricted cash at end of period $
Reconciliation of cash, cash equivalents and restricted cash reported in the
consolidated balance sheets:
Restricted cash included in other current assets
Total cash, cash equivalents and restricted cash shown in the statements of cash
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized accounts receivables $
GAAP Excluded for non-GAAP measurement Non-GAAP
Amortization of purchased
intangible assets Legal settlements and loss
contingencies Impairment of long
lived assets Restructuring
taken in facilities Equity compensation Contingent
consideration Other non-GAAP items* Other items
Other assets impairments, restructuring and other
Share in (profits) losses of associated companies –
Net income (loss) attributable to non-controlling
The non-GAAP diluted weighted average number of shares was 1,112 million for the three months ended March 31, 2022.
Non-GAAP income taxes for the three months ended March 31, 2022 were 18.5% on pre-tax non-GAAP income.
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
Adjusted EBITDA reconciliation
Impairment of long lived assets
Restructuring costs
Costs related to regulatory actions taken in
Equity compensation
Contingent consideration
Other non-GAAP items (excluding accelerated depreciation of $1.3 million)*
intangible assets Legal settlements
contingencies Impairment of
long lived assets Other R&D
consideration Other non-
items* Other items
Share in (profit) losses of associated
companies – net
Non-GAAP income taxes for the three months ended March 31, 2021 were 17% on pre-tax non-GAAP income.
Other R&D expenses
Other non-GAAP items (excluding
accelerated depreciation of $5 million)*
Revenues $
Segment profit $
§ Represents an amount less than $1 million.
North America profit $
Total reportable segment profit
Consolidated income (loss) before income taxes $
Segment revenues by major products and activities
Generic products $
Proceeds from sale of business and long lived assets
Free cash flow $
Ran Meir (267) 468-4475
Yael Ashman +972 (3) 914 8262
Kelley Dougherty (973) 832-2810
Eden Klein +972 (3) 906 2645
Source: Teva Pharmaceutical Industries Limited


text:
Leftist Reporter Takes In Muslim Refugee… Bet You Can't Guess What Happened Next?
Don't believe all the heart-wrenching footage of refugees you see on TV.
The reality is, the many people flooding Europe for handouts aren't innocent mothers and children. The toxic Socialist policies of the U.K. and other nations have opened the door to leeches. These "children" have flooded the system, abusing these nations' handout programs.
That is what one journalist from England, Lynn Barber, found out the hard way.
From Mad World News:
Daily Mail reports that Barber was initially ecstatic to rehome Mohammed, who claimed to be a persecuted Sundanese political refugee. The Muslim migrant told Barber that he was granted asylum status after sneaking into the UK through people-smugglers and, after being detained by Italian authorities, freely traveled to Britain as a refugee. Soon, however, the truth surfaced.
Barber explained that Mohammed became belligerent and aggressive, trashed her home, began smuggling drugs into his room, ran up her internet bill downloading excessive amounts of pornography, and continuously abused the taxpayer-funded medical and welfare benefits he was so generously given. Mohammed informed Barber that although she owned the house, he was going to "treat her like his mother," which entailed her acting as his personal chef, maid, and dry-cleaner…
Then came the kicker. When Mohammed discovered that Barber was going to publish a memoir about her ordeal to "show readers you don't have to be a saint to take in a refugee — you just have to have a spare room," he flew into a rage and mocked her stupidity by confessing that he's not a real refugee but a welfare leech who comes from a wealthy family.
Imagine my surprise (spoiler: I'm not). Time and again we are learning about these kinds of abuses in Europe and around the world. While there are people suffering from the war in Syria, hundreds if not thousands of "refugees" are abusing the system. So-called children turn out to be grown men, who go on to harass, harm, and sometimes even kill the families that welcome them into their homes.
This man admits he only came to Europe to abuse their benefits. Because if he stayed in his homeland, you know, he'd actually have towork for his food.
Yet because of the political correctness and stupidity of England and the rest of Europe, leeches like Mohammed are destroying their societies.
But will the people of Europe—and their leaders—stand up to this kind of insanity? Not likely.
Sadly, she gained no wisdom from the experience that will do her any service, ultimately affirming that she's hoping to take in yet another refugee in the future. In fact, Barber seems to think that vowing to only rehome "much more deserving" migrants will prevent this and worse from happening again.
Like most liberals, Barber built up this fantasy in her mind of taking in a poor, destitute family of sweet, innocent people. People who would worship this wise, liberal woman for her generosity. Even when faced with the reality that such people do not exist, she clings to this obsession.
The UN Refugee Agency reports at the time of this article's publishing that only 6.5 percent of migrant arrivals are Syrian. A whopping 72.5 percent are men, although this figure doesn't take into account the recent report from Sweden which confirmed that age testing proves 75 percent of child refugees are also adults.
It's like an entire Continent of people are marching off a cliff into oblivion. They willingly expose themselves to death and destruction, just to virtue signal their righteousness.
At least we can learn from their idiocy.
Source: Mad World News
MSNBC Hired New Reporter, HE IMMEDIATELY Tried To Get Wall Funding Shut Down!
Muslim Sees "Pork-Eating White Girl" And Responds Like A Terrorist, Police IGNORE Everything

redpajama_set_name: RedPajamaCommonCrawl


Congratulations to Heath Benson as the winner and new owner of a Benelli Super Nova Shotgun!
Thanks to everyone who helped the pipes and drums with their first fund raiser. Just over $3,000 was raised to help buy instruments.
As the members continue to meet and practice, all of you helped us get one step closer to our goal.
We are all excited with the future tradition of our own Pipes and Drums corps.
Pipes and Drums have currently paid back there Loan from the Association. Money was used to purchase instruments, and they are very excited about up and coming projects and events.


text:
$LOAD_PATH.unshift File.expand_path('../../lib', __FILE__)
require 'action_mailer_auto_previews'

redpajama_set_name: RedPajamaGithub


Welcome to The American Horror Story Fan Podcast: Hotel. This the unofficial podcast about the hit FX Horror Television show American Horror Story by fans for fans as brought to you by HorrorNewsTV.com, DocRotten.com and GruesomeMagazine.com. Now in its fifth highly anticipated season, the award winning genre show is set to push even more boundaries and break even more unimaginable taboos with Hotel. The theme this season is the supernatural and deadly trapping of the enigmatic Hotel Cortez!
Returning to co-host the fan podcast are Doc Rotten and Thomas Mariani. However, this season, they are being joined by their fellow Hannibal Fan Podcast co-hosts Dave Dreher and Christopher G. Moore. Each week they will recap and review each episode. Tonight, they are looking forward to the upcoming season with a special episode ZERO show to examine the themes, characters and promise of the what is known about Hotel thus far: which actors return; who is added to the cast; and, what is all this about Lady Gaga.
Things to look forward to after the recap each episode are Thomas & Dave providing their favorite Crazy Moment of the Week of the week and Doc & Christopher shares their favorite Outrageous Theory of the Week. Out of all the nutty things that show creators Ryan Murphy and Brad Falchuk could possibly shove into a single episode, what could Thomas & Dave possibly settle upon? And what theory could possibly come out of Doc & Chris' warped minds to shed any light into the Hotel's visual treats of wonder and horror? Listen to the podcast and find out.
We also want to hear from you! The American Horror Story Fan Podcast is designed with the fan in mind and listener feedback is encouraged. That's right, we want to hear from you! To help you out, we have a Speakpipe account set up for you to leave your Voice Messages. Click on this link and leave Dave, Christopher, Doc and Thomas your thoughts. What are your theories? What was the craziest moment of the show? Who's your favorite character? Which character do you despise the most? The service is free and no number is required, all you need is a PC and mic.


Students and staff at Northview Elementary School are mourning the loss of two students, some of the five children who were killed in an early-morning crash in Bowie on Feb. 2.
London Dixon, 8, was in the third grade at the school. Paris Dixon, 5, was a kindergartner.
Maryland State Police said the sisters and three other children, Zion Beard, 14, Rickelle Ricks, 6, and Damari Herald, 15, of Washington, D.C., were believed to be in the back seat of a Chrysler Pacifica that crashed at 5 a.m. Feb. 2.
While traveling north on Route 301 in the area of Pointer Ridge Road the vehicle traveled off the left side of the road and into a line of trees. All five children died, and police said preliminary evidence shows that they were not wearing seat belts.
The driver and the Dixons' mother, Dominique Taylor, 32, and a passenger in the front seat, Cornell Simon, 23, were injured. The cause of the crash is still under investigation, a state police spokesman said Wednesday.
At Northview Elementary, the two girls are remembered by their teachers for their artistic talent.
Paris always used to call herself an artist, and her kindergarten teacher Amy Pierson said she used a lot of detail in her pictures, even in September when classes were just starting.
Paris was a social butterfly with many friends and would compliment her every day, Pierson said, and loved doing songs and dances.
"She worked really hard to make the progress that she did while she was in kindergarten," Pierson said.
Last week a specialist did some activities with the children to deal with their grief, such as listing the things they miss about Paris.
London also loved to draw, her teacher Tiffany Smith said, and had a passion for anime. She made her own comic books.
She would draw figures in a style with big eyes and heads and small bodies, and in recent days other students have been trying to emulate it, Smith said. She used pen and marker.
"A lot of the students, they are like 'we miss her drawings,' 'we miss talking to her about it,'" Smith said.
She's been finding the drawings in recent days in her room, in London's cubby and in the library. She also started a little recess art club, Smith said.
Smith said the girls loved each other very much. London would leave early to make sure Paris had her coat, or knew they were walking home.
The school plans on memorializing the sisters in the yearbook.
London and Paris' father Chris Dixon set up a GoFundMe page to help raise money for funeral costs for the girls and their cousins. That fundraiser exceeded its goal, raising nearly $17,000 in nine days. A funeral for the children is scheduled for Saturday at First Baptist Church of Glenarden.
An update was posted on the page Wednesday morning.


text:
Gordon Ramsay spills secret to perfect Christmas turkey and mistake people make
For most, the star of Christmas dinner is a turkey.
So, to make sure it's cooked to perfection Gordon Ramsay has shared his top tips and the common mistakes you're making.
The 54-year-old chef shared the advice on YouTube where he walked through the lengthy process from preparing the turkey to making the most delicious gravy to serve it with.
He said: "Turkey is a very lean bird and it can dry out, so it's very important we help it to cook perfectly."
In the tutorial, he cooked a 5kg bird which he said is enough to feed eight people comfortably.
Buttering up
"The secret of success for a great Christmas dinner is making sure the turkey doesn't turn out dry – and it's all in the preparation," said Gordon.
The trick to the perfect turkey, according to the chef is to keep the bird "incredibly moist".
To do this, simply sprinkle salt and pepper into a bowl of soft butter, and add a dash of olive oil, the zest of two lemons and their juice.
"This gives the flavoured butter a wonderful citrus zing."
Then crush three cloves of garlic and chop a generous handful of parsley before giving everything a good mix.
Preparing the bird
To season the bird, sprinkle salt and pepper inside the cavity.
Then cut two onions in half and pop them in too, as they roast, they steam inside the bird, giving it a "lovely sweetness".
Put lemon and a couple of bay leaves inside the cavity too to balance the flavours.
Apply the butter mixture under the bird's skin, being careful not to tear it as the butter will run out, then massage what's left all over the top of the skin, covering it entirely.
This can always be done on Christmas Eve to save you a bit of time on the big day, just cover the turkey in tin foil and leave it in the fridge until you're ready to put it in the oven.
Cooking the turkey
When you're ready to cook the turkey, preheat an oven to 220C.
Pop it into a roasting tray and drizzle olive oil all over. "This makes it nice and crispy, and stops the butter from burning," said Gordon.
Cook the turkey for 10 minutes – this browns the bird quickly.
Remove it from the oven and baste it with the juices, before draping smokey, streaky bacon over the top and baste again.
"The bacon protects it," he said. "It stops it from drying out and will give the gravy a wonderful base."
Then turn the oven down to 180C and start roasting the meat.
For Gordon's 5kg bird, it was cooked for two-and-a-half-hours – 30 minutes for every kilo – basting every so often.
When the time is up, stick a knife into the bottom of the thigh to see if it's cooked. If the juices run clear, it's done.
"That's 90% of your work done," said Gordon.
Resting the meat
The "secret" to a perfect turkey though, is resting it.
"At the meat relaxes, it reabsorbs its juices, making it succulent and tender, plus it will be easier to calve.
"The flavour will be 10 times more exciting once it's rested."
Gordon added: "When I first got the chance to cook Christmas lunch for the chefs in Paris, they taught me one crucial thing: I was only 21 at the time and they made me rest the turkey for as long as I had cooked it.
"I'd cooked it for three hours, so I rested it for three hours. What a difference – incredible!
"It might seem like a long time to let it rest but, remember, the turkey doesn't need to be piping hot because it's being served with hot gravy."
Making the gravy
For his video, Gordon made a turkey gravy with cider and walnuts to give a "wonderfully nutty flavour".
The first thing to do is to drain the excess fat from the roasting tray, and put it on the heat.
Then, strip the bacon from the turkey and remove the onions and lemon from the cavity before cutting it all up and putting them into a roasting tray.
Add a couple of sprigs of rosemary to give it a "lovely aromatic punch", then fry.
As you do so, add in three chopped tomatoes to help thicken the gravy.
Then remove the wings and trimmings from the cooked bird and add them to the tray as well as some dry cider and the juices from the rested turkey from earlier.
Once the liquid has reduced by half, crush the veg and turkey with a masher, pour in some chicken stock and reduce again.
When it's ready, sieve the mixture, using the back of a ladle to squeeze the juice through.
Add a sprig of rosemary and leave it to infuse "ready for the finishing touch".
You can also add crushed walnuts to the bottom of the gravy boat for added flavour.


61-key touch response keyboard that features 550 natural sound voices.
With a stunning variety of voices and styles, the PSR-E363 opens the door to a world of musical enjoyment. Hone your technique with the onboard lessons, then when you're ready, connect to a portable music player and use the unique Melody Suppressor function to jump in and play right along.


text:
Thomas Glanzmann
Position: Non-executive Vice Chairman
Type: Other External
First appointment: 05/04/06
Last appointment: 27/05/16
Mr. Thomas H. Glanzmann has served as director of Grifols, S.A since April 2006 and as non-executive Vice-President since 1 January 2017. From 2006 until 2011 he was the Chief Executive Officer and President of Gambro AB. Previously Mr. Glanzmann was the CEO and Managing Director of HemoCue AB. Between 1988 and 2004 he held various positions at Baxter Healthcare Corporation: Senior Vice-President and Senior Corporate Officer of Baxter Healthcare Corporation; President of Baxter Bioscience; Chief Executive Officer of Immuno International; and President of the European Biotech Group. Between 1984 and 1988 he worked at Philip Morris becoming country manager for Norway, Denmark and Iceland.
He holds a degree in Political Science by Dartmouth College, United States, and a M.B.A. from IMD (Lausanne-Switzerland, a B.A. and a Board of Directors Certification from the UCLA Anderson School of Management, USA.
Mr. Thomas Glanzmann was a Senior Advisor to the Executive Chairman and a Managing Director at The World Economic Forum in Davos from 2004 - 2005 and the Chairman of the Plasma Protein Therapeutics Association (PPTA) between 2000 and 2001
He serves as a Director on the Boards of Sulzer AG, and Alkahest Inc., as well as Healthcare Advisor to Madison Dearborn and Partners and General Partner in Medical Technology Venture Partners in California, United States.


It is the week of the 4th of July. That means the United States is celebrating the signing of the Declaration of Independence, breaking free from the British Empire, and becoming an independent nation. With the holiday underway, it seems like a great time to reflect on the concept of freedom (including cognitive liberty) and what it means to each and every one of us.
In this episode, Joe and Kyle reflect on the concept of personal freedom, cognitive liberty, and the impact that the War on Drugs has on the American people. It seems to be the consensus that the War on Drugs is failing. The policy has huge negative consequences on people across the globe, and significantly marginalizes minority groups and people of color.
As psychedelic research continues to progress in the academic and scientific realm, many people are still subjected to arrest and imprisonment because of this failed policy. Kyle and Joe share their thoughts about the pursuit for cognitive liberty and personal freedom.
Do you think that exploring one's own consciousness, whether through plants or other drugs, be illegal? Why should a person have to "ask permission" to have an experience with their own body, mind, and spirit?
Let us know your thoughts about this topic.
Joe and Kyle also talk about their new upcoming course, Navigating Psychedelics: Lessons on Self-Care & Integration. Be sure to check out this course and sign up TODAY!
We are giving away a SPECIAL offer just for the 4th of July! Receive 10% off our Earl-Bird special with the coupon code "freedom" when you check out. You do not want to miss this offer!


In the next area Eric notes that the turf is nicely establishing but we've got a few problem spots. How do we go about evaluating what's going on here? Brian explains, this area is an example of an existing turf that was put in about a year ago. One can see some areas in the turf where it's a little patchy and has some open areas. A lot of his comments about this stem from conversations with the homeowner. This is common for Brian he talks with homeowners to figure out what's going on with the situation. One do they have a dog, because dogs using the bathroom on a turf can cause a high concentration of nitrogen and that can cause patchy bald spots or two it could be a product of not enough watering which means that the grass would be going dormant, or three it could be too much watering which can cause a fungal infection. In talking with this homeowner Brian has learned that this area hasn't had an irrigation system in the past so it wasn't watered heavily. Number two they don't have pets and so we know this is not a dog issue, and number three the homeowners said that they are not the best at watering their grass, so this is kind of a classic example of the turf not getting enough water. So the grass is starting to go dormant in particular areas, it starts getting patchy and those patchy areas will grow and grow. This doesn't necessarily mean that this fescue grass is dead, it's just going dormant from low water at times and that's what you see here.


2. The Best Chefs in The World! They just love opening resturaunts in Vegas, so be sure to scout the casinos for your favorite culinary master.
3. Abundent Parking! Unlike other tourist destinations (um, Los Angelos, New York), Las Vegas has tons of parking whereever you go, which majority is FREE! So you can skip the extra hour leaving your house in order to find somewhere to park and usually pay.
4. Pool Parties! We may not have the beach (which is only a 3 1/2 hour drive away) but we do throw killer pool parties at all the casinos with live DJ's, full bar, gaming and the sexiest, fun loving crowd in Vegas!
5. Hiking, Snowboarding, Rock Climbing, Jet Skiing! Love the outdoors, Vegas has something for all seasons.
7. Concerts, Shows, Celebrities! Never a dull moment, there is always a concert, daily show productions, and celebrity sightings daily…because Las Vegas is just fabulous!


text:
CAROLINE DELK
storyteller, reader, student
For this blog post, I decided to make it fun. In doing so, I'm going to list my favorite things/people. The things in the following list mean a lot to me and I want to share them with whomever decides to read this post. And I think it'll be a fun way to learn something about me that you didn't know before. Or you might find out that I'm secretly crazy. Either way, it'll be fun.
1. BOOKS – now, if you didn't know that already, then you truly don't know me. Because of my love of books, I found what I wanted to do with my life: literary agent (more on that a little later). I mostly like all genre of books except for a few. My favorite books fall under the following genres: women's fiction, romance, young adult, adult contemporary, fanfiction, and non-fiction. Just for fun, here is a list of my favorite authors (who I will recommend ALWAYS): Jodi Picoult, Nicholas Sparks, F. Scott Fitzgerald, Amy Reichert, and Heather Cocks & Jessica Morgan (these two are a duo).
2. LITERARY AGENT INTERN – to continue on with the book theme, one of my favorite things is working and interning with Brent Taylor. I've been his intern since April and I've learned so much. And I am truly enjoying every minute of it. Being his intern has allowed me to start thinking about what kinds of books I would want to represent when I (hopefully) become an agent. Every time a manuscript shows up in my email, I get so happy. So, Brent, thank you for taking me on as your intern. It means the world to me.
3. WRITING – writing has always been a big part of my life. Ever since my sophomore year of high school, I believe. I still have the manuscript from the very first "novel" I've ever written. Although it's embarrassing, it's something I'm super proud of. I can only hope to be able to write like Jodi Picoult one day. Not only that, but I've made one of my best friends ever because of writing. Amanda, thank you so much for forgiving me after I dropped icing on your computer (HAHA). And thank you for putting up with all of my craziness. It truly means a lot to me. I cannot wait to really dive into the book we're writing together.
4. ONE DIRECTION – I bet you all were wondering when this would pop up, so here it is! First, I would just like to say to those who think it's a little weird that I like a boyband: whatever, get over it. Harry, Niall, Liam, Zayn, and Louis are all either my age or a year or two older than me. It's not like I'm obsessed with guys younger than eighteen. Secondly, the members of this band are just so amazing. They care about people. Harry is fighting for equality all over the world. Louis spends a lot of time raising money for children who are dying from cancer. As a band for Red Nose Day, they took the money for a music video for "One Way or Another" and donated it to those in Africa. And finally, together or apart, they make some pretty great music. Their music has gotten me out of some pretty hard times. If I'm stressed, upset, or sad, I know if I listened to 1D, I'll be happy. There is just something about these guys . . .
5. THE ROYAL FAMILY – Queen Elizabeth II, Prince Philip, Prince Harry, Prince George Alexander Louis, Princess Charlotte Elizabeth Diana, and William and Kate, Duke and Duchess of Cambridge are some of my favorite people on this planet. I've been mesmerized by their existence for the longest time. Everything about them is perfect. And because of them, I have made some great friends who are just as obsessed as I am. More specifically, Gail Werner. The moment something big happens, we are instantly messaging each other about it. It will definitely always be one of my favorite things.
6. TRAVEL – granted, I haven't actually traveled to these places I'm about to list, but the idea of one day being able to sends adrenaline through my body. London and New York have been on my mind all of my college career. So much so, they made their way on to my graduation cap. New York has always been a place I've wanted to live in. When I started college, I knew I wanted to work within publishing, I just didn't know what. But the one thing I did know was that I needed to be in New York. That has changed quite a bit lately. Now, I would love to live and work in London. It would be the perfect fit for me, I just know it.
7. FAMILY – last year, my grandfather on my dad's side passed away. At his funeral, I met some of my family I didn't know or remembering meeting when I was younger. But his funeral pushed that side of my family to get together for reunions. In the last year, we've had three, and I'm so grateful for having these chances to get close with the family I didn't know I had. I have gotten super close with some of my "third" cousins. Zach was the first one I met (I met him at the funeral). He accepted me into the family like it was nothing. Allie was the second one I met (I also met her at the funeral). She's the one I go to whenever I have a problem. We've gotten so close in the last year. And, finally, Kameron. I don't think I can put how much he means to me into words. He's stuck with me for the last year, through all my panicking about graduation and after graduation, relationship issues, and so much more. Even though he yelled "Go Big Red" while I crossed the stage at graduation, I think I'll keep him. Oh, and my sister is pretty great too. My best friend for life for sure.
8. PETS – I love all of my pets. I don't know what my life would be like without the dogs and cats that are in my life. Sometimes they drive me up a wall, but I wouldn't change how things are. EVER.
These are just some of my favorite things, but they're the most important. They make me who I am and they allow me to be myself. Without these things, I don't know who I would be.
Different Directions
Top left: Harry Styles' album cover.
Top right: Niall Horan's "Slow Hands" cover
Bottom left: Liam Payne's single cover
Bottom right: Louis Tomlinson's solo cover
If you know me at all, then you know just how much I love One Direction . . . especially when they were still together as a boy band. For a little over a year, the members (Harry Styles, Niall Horan, Liam Payne, and Louis Tomlinson, just in case you didn't know) have gone in their own direction (HAHA, get it?). But that hasn't stopped me from being one of their biggest fans. So, I'm taking this blog post to talk about and share my opinion on all of their new music. And because I'm me, I'm going to write about them from youngest to oldest, just in case they happen to see this and think I'm playing favorites (But that Harry Styles, though. What a babe!).
Okay, being the only member of 1D to have an entire album out, I just want to take a second and thank him for gracing us all with his angelic voice and his beautiful lyrics once again. Also, I just love how every song is different. Meaning, a nice mixture of rock and pop. It truly fits his voice. Since it came out on May 12th, I think I've listened to the entire album over seventy-five times. Yeah, I'm that person. I might claim that I love ALL of the songs, but I'm a human and I have my favorites.
"Ever Since New York" is probably my favorite, I'm not going to lie. There is just something about this song that pulls me in every time it plays on my phone. I've found myself singing it at random times throughout the day, also. Maybe I do have a problem?
"Two Ghosts" is just beautiful. I honestly can't think of a better word than "beautiful." Whether this song is actually about Tay Swizzle (EW) or not, everything about this song screams Harry Styles. It's sweet and light and just an all-around amazing song.
"Sweet Creature" just makes me so happy. Now, I'm not sure why H. Styles is calling this person a "sweet creature" instead of something like "sweet woman" or "sweet man" but I totally dig it. And I totally dig the song and loving someone so much that, no matter what happens, "sweet creature, wherever I go, you bring me home."
And, finally "Sign of the Times." When I first heard this song, I was like "why is it so flipping long?!" but then I understood. Not only did I thoroughly enjoy the high notes he hits in the song, I just love the meaning behind it. Styles said in a recent interview that the song is about everything that's been happening in world. More specifically, Brexit and Trump.
Those four songs are my personal favorites. But the whole album is amazing. Whether you LOVE One Direction and Harry or not, you should definitely listen to his album titled "Harry Styles." The passion he has for music comes through in all the songs. It's definitely worth a listen.
Being the first one of the members to release their first single, Niall baby, you are amazing. I just want to point out how far this Irish boy has come. When 1D first started, he didn't have a lot of solos in the songs. But as the years went on and his voice got stronger, he was able to have more singing parts. And now, he has two solo singles out and I couldn't be more proud of how far he's come. Every time he announced when each of his singles would drop, I stayed up until midnight to download them, and then I would listen to them once or twice before going to bed. And I've been obsessed with them ever since.
This Town," which came out in September of 2016, is so Niall. In saying so, I just mean that it's sweet and adorable just like him. And I know that's a weird statement given that it's a song about heartbreak, but the words he uses to describe everything he still wants to say to "her" or "him" is so cute. Is that the right word? I'm not sure, but it definitely works. And I can imagine how it feels to see "her" or "him" just by listening to his words.
"Slow Hands." Two words; HOLY CRAP. Excuse me, but where did this Niall Horan come from? I mean, there were sexual songs on the last 1D album that he apparently helped write BUT WHAT THE HECK. And the fact that this song is categorized as "funk-pop" is amazingly beautiful, and 100% true. Every time I listen to it, I just groove. It's so catchy, that even my sister has it downloaded on her phone. CRAZY.
All in all, the first two singles have completely blown my mind. And I cannot wait for the entire album to come out later this year. Why he's making me wait so long, I have no idea. But from what I've heard from Niall so far, this album is going to be amazing. And I CANNOT wait to hear him perform these two songs LIVE this summer when he's here in Indy. Honestly, if you haven't given these two songs a listen yet, you all probably should. They're amazing.
I just want to say a quick congratulations to this new father! Little Bear is going to be the cutest kid ever, I just know it. And I want to mention how amazing Liam is too. He's been away from his newborn son to finish the single he just dropped with Quavo. I know that can't be easy, but I'm so happy to have some new Payno music!
1. "Strip That Down" is everything that I pictured Liam would make outside of 1D. Speaking of 1D, I think I'm the only person who is not upset about one line in the song that goes "You know I used to be in 1D, now I'm out free." I don't take that as he's happy to be in a hiatus from the band. I think he's just happy to make the type of music he wants. Because everyone knows that a song like this would have never made it on a 1D album. Anyway, I digress. The song is so good, that once again, my sister has downloaded it on her phone. This song just works for Liam. I don't exactly have the words for why, but just believe me. Would I steer you wrong?
This song is so good, I honestly can't wait to hear what else he has up his sleeves. Maybe more collaborations? Maybe a song with another member of the Migos? Who knows, but I know that it will be good. And I'm happy to listen to anything he will make. Especially since I'll be able to see him perform live this summer as well! Exciting times for this 1D fan!!
Being the second member to release a single, Lou, you are just as amazing as the rest of them. Especially since he released this song shortly after his mother passed away from Leukemia. He was able to perform his song with Steve Aoki on the X Factor and dedicated it to his mom. And, just like Niall, I know how far Louis has come. He didn't get very many solos on the 1D albums at the start, but he clawed his way up just like Niall did and won the hearts of Directioners all over the world. On December 10th, 2016, he took the world by storm once again.
1. "Just Hold On" was rumored to have been written for his mom when she found out that she had cancer. Whether it was for her or not, it's a great song for anyone that's going through something difficult. A line in the chorus goes "if it all goes wrong, darling just hold on." On top of that line that appears more than once, the music behind the words is so upbeat, thanks to the lovely Steve Aoki. I honestly don't know how to describe this song other than perfect. Perfect for Louis. Perfect for everyone.
I don't know if Louis plans on putting out an album anytime soon, but I think I can live with this one song for right now. Anytime I find myself upset or in a weird mood, I turn to "Just Hold On." Something about it makes me feel safe. Then again, anytime I listen to 1D, I feel safe.
If you've made it to this part of my post, I applaud you. And I want to thank you. I love sharing what I love with other people. I love Harry Styles, Niall Horan, Liam Payne, and Louis Tomlinson a lot more than I probably should, but I don't care. And I'm definitely not ashamed of it, either. Actually, my heart is so full of happiness and pride, it might burst. Not only do they make great music, but they're great human beings, and they definitely deserve to be bragged about. Anyway, listen to their music!! All four of them will blow your mind. If not, oh well. I'll love them enough for all of us.
Vessels: A Love Story Book Review
Vessels: A Love Story
By Daniel Raeburn
Trade Paperback, 176 pages, $23.95
When Dan, a writer with a passion for underground comics, and his wife Bekah, a potter dedicated to traditional Japanese ceramics, met through a mutual friend at a Memorial Day party, they fell in love quickly. "Of all the women I've ever met," Dan told a friend, "she's the first one who felt like family." But after spending Christmas with Dan's family, tragedy struck. The baby, whom Bekah and Dan named Irene, wasn't moving and Bekah didn't feel right. The following day, Bekah went to the doctor only to find out that Irene was dead. Leaving her with the only decision: deliver a stillborn.
After the devastating loss of Irene, Dan and Bekah were stuck in a cycle of being depressed and not wanting to live. Bekah spent most of that time being stuck on bedrest while the rest of the world sped past her. She got to the point where she was tired of everyone else doing the work for her and willed herself out of bed. "She didn't want to work with anyone who'd known her before the birthday. When her fever receded she got dressed and rode a bus to the skyscrapers downtown, where she took a job in an office where no one knew anything about her but her name" (pp. 47).
A little over a year, their wedding and honeymoon later, Bekah was pregnant again. Knowing and remembering what happened with Irene, Bekah and Dan were on edge about everything. And in hopes of not jinxing this pregnancy, Bekah and Dan didn't tell anyone. The baby was breech, so a C-section was scheduled, and the baby was delivered with no problems. They named her Willa.
Based on Daniel Raeburn's acclaimed New Yorker essay, Vessels: A Love Story is the story of how he and Bekah fought and clung to each other through a miscarriage in December of 2003, a still-birth in December of 2004, a C-section in May of 2006 (Willa), a miscarriage in December of 2008, and then finally having Hazel and joyfully becoming parents. In prose as delightful as his wife's pottery, Raeburn recounts a marriage cemented by the same events that nearly broke it.
Vessels is an unwavering, immensely moving story of intimacy, strength, and love.
J Mac at BSU
** First off, just in case this somehow makes it to Jesse himself, I just wanted to thank you for making all my childhood and teenage dreams come true. I never thought I would see you in concert, let alone meet you. So thank you. For everything. **
Jesse McCartney,
All right, let me tell you a story. When I was about five, I was introduced to the lovely boyband called Dream Street. I wasn't really into music back then. Granted, I was only five years old, so what did I know? Anyway, my sister and I were really into everything that was involved in Dream Street, especially when we picked our favorite members. Courtney's favorite was always Chris Trousdale. And, Jesse, you were always my favorite. My five-year old self always saw something special in you. Believe me when I say, seeing something special in you hasn't stopped. And probably never will.
When Dream Street broke up in 2002, my heart broke with it. But it definitely spurred my love for all boybands. But I never stopped being a fan of yours, Jesse. And when your album "Beautiful Soul" came out in 2004, everything was perfect. I was only ten years old at the time, but every song on that album meant so much to me. I didn't know it at the time, but your songs have helped me through every rough patch I've ever endured in my life. More specifically, "Because You Live." It just spoke to me. But don't think I have forgotten about your other three albums. They were equally just as amazing as "Beautiful Soul." All yours songs have touched me in a way that I can't seem to put into words at the moment.
Given everything that I just told you, when I say that seeing you, Jesse McCartney, in concert has been in preparation for years, I mean it. Anytime he was in Indiana (I don't remember all the specific dates), I was either too young to go to a concert or my mother didn't think I was ready for it. And then, on my way home from Ball State one weekend, your face pops up on my facebook page and announces that you will be coming to BSU. When I say I freaked out a little bit, I'm lying. I completely lost my shit. I'm pretty sure I screamed. I think I might have even started hyperventilating. But in the best way possible. It's my senior year and I wanted to go out with a BANG. Seeing you in concert and taking a picture with you made my senior the best year here.
The morning before the concert, I was too excited to do anything else but think about hearing "Beautiful Soul" performed live. How pathetic, right? Anyway, I took my sister back to her dorm for her to get ready for her class. And then I got ready. I showered, did my make-up, and counted down the hours until it was time to head over to campus. I was so excited and nervous to meet you that I let my sister do my hair so I looked perfect for the picture we would take together. Shortly after, my friend Monica showed up and we were ready for our night to begin.
We got to campus around four in the afternoon and spent some time in Woodworth, since it was the closest to Pruis. We enjoyed some fast snacks, taking selfies, and just talking about everything going on in our lives. And then it was finally time. We got there just in time to be at the beginning of the second row of people to meet you. We waited for over an hour, but it was so worth it. When it was finally our turn to take our picture with you, I was so nervous that I thought I was going to pass out. But seeing your smiling face made everything so much better. You greeted us with "Hey, guys" and a smile. I shook your hand, even though I wanted to go in for a hug, but I didn't want to be too forward. So I was just happy that I got to stand close to you. And when you said "Say hi to Instagram," I didn't know what to do, so I did this stupid wave thing? I don't know, I was just so nervous. Meeting you took about a whole twenty seconds before we were rushed off. But I understood. I don't regret a thing from that night.
Fast forward to you gracing us with your presence on the stage, and starting the show off with "Leavin'." I remember everything from that night. Everything from me screaming so much and so loud that my throat hurt instantly to watching you choose some random girl in the front row to sing "The Stupid Things" and another girl to hold your water bottle, and finally, to you ending your stay at BSU with singing "Beautiful Soul."
Everything about that night was a dream come true for me, and probably for most of the others that saw you. I don't know how to explain how much you mean to me, Jesse. But I thank you and eagerly await your new album.
Sample Texts
Email: cmdelk@bsu.edu
Facebook: facebook.com/carolinedelk
Twitter: @carolinemdelk


Oof, right now the last thing I really want to talk about is sweet things. I had a busy, fun day filled with friends and sugar. It was the first really spring-like day of the year and we got out and enjoyed it, and earlier Z and I shared a plethora of really good cookies. I picked out Paradise, Epiphany and Rhapsody, which were all good but Paradise was definitely my favorite. I'm really into lemon right now and the bright zing of lemon in those cookies was so good. Plus, I got an almost whole macadamia nut in one bite – it doesn't get any better than that!
After we nibbled most of the way through the cookies, we attacked my very first red velvet cupcake, provided by Miss Iron Cupcake Earth: Coffee herself. We have three others but I had never tried red velvet (because I'm so northerly I guess) so I wanted to eat that one first. It was pretty much the cakiest cake ever. I do totally get the appeal, and I LOVE cream cheese frosting (and Carrie's frostings are always so smooth and delicious!), but it was too rich for more than a couple bites for me (soooo buttery…mmm). This was no problem for Z; he totally loved it and was more than happy to devour what I couldn't finish.
This smelled so amazing and would probably make phenomenal cotton candy or something equally ethereal.
Of course, I had to bring some goodies along with me if I was going to be meeting up with friends! I'm still not over my obsession with pink and brown, so I went with that and took advantage of some leftover strawberry puree sitting in the freezer. I combined it with some granulated sugar for macaron shells and added it to a rich chocolate ganache filling for some adorable slightly tangy and not-too-sweet little macarons.
Much smaller and more my size than the last ones!
I also recently got some nice orange blossom and rose extracts and wanted to make something else to pad out my little treat-boxes, so I kept with the color theme and made rose marshmallows (even my treat boxes are brown and I use pink ribbons…plus they're the colors on my business cards…they're just so DELICIOUS together). It was my first time working with such a concentrated flower extract and I added a bit more than I would have liked, though not enough to make them taste "soapy" or anything – just very very sweet and strong.
These turned out much firmer than past marshmallows, but in a good way.
I ended up tossing them in cocoa powder and that fixed them right up. They are absolutely dreamy with the bitter chocolate on the outside and the super sweet, incredibly fragrant rose marshmallow inside. Flowery marshmallows are definitely my favorite kind so far.
The decision to make marshmallows only came after some matcha macarons failed. Well, they were sort of ok, but I piped some of them too close together and the batter was runnier than I've dealt with before for some reason. They did develop feet and a top crispiness and everything, but most of them ran together and stayed pretty wet in the middle. Plus the ganache I made for them, while insanely good with matcha (made with 87% cacao dark chocolate) ended up a bit too stiff to be easily pipeable. It WAS great, however, for rolling truffles. I beat some sweetened matcha into it and then rolled the truffles in more sweet matcha. By the morning, however, my sweet, grassy green little balls had become tacky – the ganache had somehow absorbed the matcha. While this made them absolutely delicious, it made the truffles look moldy. Shortly before we left, I tried tossing them around in some cocoa powder, and that, again, fixed them right up! Unfortunately I don't have any pictures of them, or even really a recipe, but they're really rich and simultaneously light tasting due to my using whipping cream as my liquid.
I'm not discouraged by my macaron disaster. I just need to be a little more careful! I have at least one hopefully killer flavor idea and will keep working with them. They're too amazing not to!
Could these BE any daintier?
Add the strawberry puree to the granulated sugar and combine fully. Allow to dry out (preferably near a sunny window) for a half hour or so, then grind with mortar & pestle. Repeat until the sugar is almost completely dry and there are no large chunks or crystals in the sugar. Meanwhile, prepare a baking sheet with a piece of parchment paper or a Silpat. If you are new to making macarons, you should use the parchment and trace circles (about 1.5″) on the back with a pencil so you have a size guide when piping the batter. Sift together the powdered sugar and almond meal. Whip the whites to a foam and gradually add the strawberry sugar to obtain a glossy meringue, then quickly beat in food coloring (you could add a lot to get brightly colored shells but I like them more pastel). Fold together the mixtures, working quickly at first and gradually slowing down as you go. You shouldn't have to use more than about 50 strokes. Test a small amount of the batter by plopping it onto a flat surface. If the top of the batter flattens out on its own, it's all set. If not, fold it a couple more times. Transfer the batter to a pastry bag fitted with a large plain tip and pipe into circles. If you're using parchment, it's a good idea to use a tiny bit of batter in each corner to stick the paper to the baking sheet, so it lays flat. Once the macarons are piped, allow them to sit for an hour so a skin can develop. Meanwhile, preheat the oven to 300. Once the hour has passed and the oven is sufficiently heated, place the baking sheet in the oven and bake for 10-13 minutes (mine only needed about 10 – any more and I think they would have been too dry inside). Allow to cool fully on the baking sheet. I piped my circles only about an inch across, so they popped off the parchment easily and didn't need any extra coaxing like the first ones. If yours do stick, however, put a few drops of water between the parchment and cookie sheet, and use a sharp knife to help dislodge any stubborn cookies. Once cooled, you can fill with the ganache.
Place chocolate and cream in a microwave-safe bowl and turn on high for 30 seconds. Stir well and microwave for another 20 seconds. Repeat until the chocolate is evenly melted (I know this obviously isn't the traditional method but it's what Joe Pastry does and for a small batch of ganache this works perfectly and dirties less dishes). Allow to cool to room temperature, then place in refrigerator until chilled and stiffened. Gradually add strawberry puree by Tbsp, whipping each addition in well. Flavor only to your liking (I ended up using up the rest of the puree, which was perfect). Chill until stiff again before piping between macaron shells. Chill 24 hours before eating.
The strawberry flavor was not as strong as I'd hoped from the plain shells, so I made the decision to add the remaining puree to the filling. It worked fantastically and after developing in the fridge overnight the tangy strawberry flavor had permeated through to the shells.
Well of course I cut them out like hearts!
In the bowl of a stand mixer, pour the gelatin into the cold water and allow to sit 10 minutes. In the meantime, bring the remaining water, sugar and corn syrup to a rolling boil for one minute. Immediately pour into the gelatin and affix to the stand mixer. Add salt and rose flavoring and beat for 8-10 minutes, or until fluffy but not stiff. Beat in the food coloring. While the marshmallow mixture is being beaten, line a small casserole dish or other somewhat deep baking pan with oiled plastic wrap (oiled side up!), and oil a spatula (silicone rocks!) as well. Pour the marshmallow into the oiled, lined pan, coaxing it with the spatula. Smooth out and cover with another piece of oiled plastic (the pan I used ended up twice as big as I needed so I just folded half the plastic over). Allow to sit 3 or more hours (I left mine overnight this time just because I started them late). Prepare a jelly roll pan with a mixture of unsweetened cocoa powder and powdered sugar (I used maybe a 3:1 ratio). Cut the marshmallow with a heart-shaped cookie cutter (really, the shape helps make it!) dusted with cocoa powder and coat evenly with the cocoa/sugar mixture. Re-dust the cutter as you go. Use a cocoa-dusted pair of kitchen shears to cut up the remaining scraps and toss them in the cocoa mixture as well. Keep sealed in a plastic bag.
I know I said I wanted to make my marshmallows corn syrup-free, but they really seem to be the most stable when made with it. And I know we don't eat much of it (not normally a lot of processed foods in our diet these days)…AND it was the last of the bottle. So…oh well. And, totally worth it.
Gorgeous contributions you made! Macarons are so temperamental, they drive me a bit crazy hehe. And good on you for making truffles out of the ganache-inspired!
I tell ya, you could package these in cellophane bags and make a bundle selling them. They are lovely looking. Perfect for a girly gathering.
What LOVELY bites of rose-hued beauty!! All of your sweet treats look deeeelightful. I saw a post for rose scented marshmallows somewhere, a long while ago (maybe Chocolate & Zucchini?) and have been dying to make some ever since. Except that I think they would be much harder than people let on, and I'm awfully lazy when push comes to shove.
Also, your macaroons? To die. For. Really.


text:
Q: No microphone working on Windows 10 and Intel mainboard I'm using Windows 10 64 Bit with an Intel DH55HC mainboard.
I am using the onboard audio device but unfortunately I can't get my headset to work.
Whenever I try to configure my microphone, Windows tells me to check that my audio device is properly configured.
No port is working, and another headset isn't working as well. How can I get my microphone to function properly?

redpajama_set_name: RedPajamaStackExchange


text:
HighlightsYoung Folks
Young Folks – {10 folk / acoustic / indie folk / alt-country / singer-songwriter jams, (guêatas aſaqɣ hubchìhicâ taa)
Young folks focuses on the best, fresh folk, acoustic, singer-songwriter indie folk & alt-country jams. Turn it up Folks!
***guêatas aſaqɣ hubchìhicâ taa=36 (Muisca numerical system)***
—In memory of Mac Davis—
Nate Todd
'Too Much'
[americana/indie folk/singer-songwriter]
Press Notes:
Nate Todd is a singer-songwriter, multi-instrumentalist, writer and producer. From performing in Colorado group Whiskey Tango, to becoming a successful music journalist, to the release of his debut EP and now LP, Todd finds himself confronting the pervasive issues that plague American society today. His forthcoming debut slated for October 30th, Revolutionary Loser, ultimately attempts to convey that the road to a better world must be traveled no matter how difficult and seemingly unending.
Folkus
'Boy All Alone'
[folk/acoustic]
Raised on the outskirts of the Rocky Mountains, Dylan James the singer-songwriter behind Folkus pulls inspiration from the land and culture that encompasses where he grew up.
A native of Calgary, Alberta, where the ever-changing weather and mood of the rockies meeting prairie's is felt in the music Folkus creates. Deep, dark, beautiful tones and soul searching lyrics layer the songs throughout his catalog. The rich and long history of folk, rock, and country music that flows through Western Canada has had a considerable influence on the direction of Folkus's musical evolution as well as an eclectic taste for world music and anything that stirs emotion.
Genre bending and melding, introspective and heartfelt, he sees his songs as stories of the lives lived and experiences had around these parts – harsh winters shape the mindsets while the rugged wilderness shows reality and inspires purity, all amalgamating to mould a sound uniquely his own.
Envisioning his debut singles as night and day, "Oh Maria" is a reflective step inside the hard and heavy half while "Blue" is a misleadingly soft and dreamy tale. Recorded over the summer months of 2020 in Canmore, Alberta, the two singles will be part of a debut EP set for release in winter of the same year.
Folkus is on a journey that has no end, a working man's musician hammering away to stay consistent and persistent and pure in search of a better self and hopefully in turn wiser songs.
'Remember'
[indie folk]
Elina is an Ivor Novello-nominated singer-songwriter from Sweden.
She's solidified a strong reputation in the industry in recent years, most notably for having co-written the multi-platinum 2016 single 'Sexual' for NEIKED, and having penned songs for Zara Larsson and Astrid S, amongst others.
As a testament to the strength of her songwriting, Elina has been nominated for several awards in her native Sweden, including winning 'Song of the Year' at the 2017 Swedish Publishing Awards and being nominated at the prestigious Denniz Pop Awards in 2015.
Following her songwriting success, Elina launched her artist career in April 2018, with the release of her cinematic debut single 'Wild Enough', which was championed by music blogs worldwide, and quickly reached over 20 million streams on Spotify. Follow up singles, 'Here With Me', 'Champion' and 'Mirage' were also released to similar acclaim, with her project having collectively amassed over 45 million streams to date on Spotify alone.
Her project has also been championed by magazines, blogs and TV shows alike, with coverage in Wonderland Magazine, Clash Magazine and The Line of Best Fit, her songs regularly featuring in the top charts on The Hype Machine, and a notable sync for 'Here With Me' on US network show The Bold Type.
Elina's songwriting comes from the heart, and she isn't afraid to write about things that aren't perfect or pretty in topic, with her music addressing self-belief in one's own ability and the fear of being seen as inadequate. Her solo project aims to break from today's strict genre formats, and instead focuses on an approach of stripped down instrumentation coupled with timeless songwriting.
N. Kerbin
'A Boy and a Man and a Satellite'
N. Kerbin is Poughkeepsie-born, Virginia-bred, Brooklyn-burnt, LA-based songwriter Nathaniel Wesley Fenton House Kerbin (who obviously spent a lot of time coming up with a name).
Formerly of the post-hardcore outfit Arrow to the Sun, N. Kerbin explores a quieter, more restrained approach. Drawing inspiration from the forthright melancholy of Elliott Smith, the instrumental experimentation of Bon Iver, and the genre-bending of artists like Choker, Kerbin's sound is at once familiar and surprising.
Rubin Kates and the Revival
'Lines of You'
Rubin Kates and the Revival consists of Rubin, who plays guitar and is the songwriter and lead vocalist; Todd Porter on drums, Manny Degrandis on bass, Jenna Gallagher on backing vocals and violin, and Chris James on lead guitar. Their debut album entitled Vivian Road was released in 2019, and featured cameo appearances by legendary blues harp player Jerome Godboo. Their upcoming album Twilight Tales is due out later this year, and will feature new songs written by Rubin and some revamped and remixed songs from Vivian Road. Rubin's songs are acoustic guitar based and lyrically driven folk-americana compositions in the spirit of Bob Dylan and John Prine.
The Dennis Brothers
'If One Thing Leads to Another'
[americana/country]
The Dennis Brothers (Dalton and Dryden Dennis) wrote this song for their sister (Dabney Dennis) when she graduated high school and left for college. Dabney Dennis also sings on the song.
Shayna Adler
'Stagecoach Sally'
[folk/americana]
Imagine a time-travelling troubadour from a medieval, whimsical world…The marvelously illustrated music of Shayna Adler is a Folk-Rock wonder of adventures and stories just waiting to be told.
Shayna's affinity for the soaring melodies of Celtic and American Folk music have shaped the bloom of her aesthetics and imagination. Her deeply descriptive lyricism exemplifies what it means to be a storyteller, and to transport a listener to another place and time.
Feminism and the enrichment of women's lives are a constant underlying theme in her songs: with heroines and female warriors portraying Shayna's empowering narratives as inspiring, yet relatable characters. Shayna's hometown is Long Beach, California, where she is a local performing artist and recording engineer.
The Dustbowl Daddies
'O Little Fire, O Little Light of Wisdom'
[country/americana]
With steel string jangle, swinging trumpet, and plenty of stomp and twang, The Dustbowl Daddies' high energy folk-pop songs combine lush harmonies, lyrical intensity, and an infectious, melody-infused, driving beat to get the dance floor hopping. The Dustbowl Daddies' new album, Boom and Bust Economies of Love, will be launched in the coming year.
The band donates most of the proceeds from its live shows and has raised more than $5000 for some of the amazing charities working in Ottawa (including the Ottawa Rape Crisis Centre, Ottawa Inner City Health, Families of Sisters of Sprit).
While the band is based in Ottawa, members Paul Saurette, Paul Tyler, Rob Sparling, Mat Paterson, Kevin Grignon, Lee Jacobs and Chris Leite hail from across the country and beyond, and remain deeply connected to places as varied as Vancouver Island, Winnipeg, Toronto, North Bay and northern England.
Between them, band members have published almost a dozen books on topics as varied as climate change, humiliation, poetry, corruption, populism, car culture, political rhetoric/communications, philosophy, international relations and beyond.
Spencer Burton
'Memories We Won't Soon Forget'
Spencer Burton came to prominence as the guitarist/vocalist for Attack In Black alongside Daniel Romano before moving on to perform with City and Colour and finally embarking on his own solo career. He's previously performed all over the world and has been featured at American Songwriter, Exclaim!, PopMatters, iheartradio and more. New single "Memories We Won't Soon Forget" is a pensive country/folk ballad that finds Burton ruminating on the images in life that stick with us for eternity, his voice floating atop layers of guitars, sweeping pedal steel, textural organ swells and accented by a gospel choir.
Jim and Sam
'After So Many Days'
[folk/singer-songwriter]
After a decade of making music together, Jim and Sam, a recently married singer/songwriter duo from Los Angeles, were not the conventionally successful band they hoped they'd be. Feeling stuck and anxious about their future, the duo made a spontaneous decision to go "all in," making a pact to play one show every day for a year. With suitcases and a guitar, the troubadours ventured out for a 365-day tour down unexplored roads and onto unexpected stages, bringing their music to new audiences throughout 14 different countries. After So Many Days, is an intimate front row seat to the highs and lows of what it's like for two people to pursue a dream, together.
Compiled by: Christos Doukakis
Tags: acousticAdler ShaynaamericanabluegrassBurton SpencercountryDennis Brothers (The)Dustbowl Daddies (The)ElinafolkFolkusJim and SamKates Rubin and the RevivalKerbin N.N. KerbinNate ToddRubin Kates and the RevivalShayna AdlerSpencer BurtonThe Dennis BrothersThe Dustbowl DaddiesTodd NateYoung Folks
Next post Abrasive minerals, No84
Previous post textures\/reverb (43)


2015/02/26 10:11:49 - INFO - Authentication (publickey) successful!
2015/02/26 10:11:49 - INFO - Secsh channel 1 opened.
2015/02/26 10:11:52 - DEBUG - Sending global request "keepalive@lag.net"
2015/02/26 10:11:55 - DEBUG - Sending global request "keepalive@lag.net"
2015/02/26 10:11:58 - DEBUG - Sending global request "keepalive@lag.net"
2015/02/26 10:12:01 - DEBUG - Sending global request "keepalive@lag.net"
Any ideas of what am I doing wrong or how can I avoid this issue?
PS: I'm running Paramiko 1.14.0 on Python 2.7.8, and Fabric 1.9.1.
se fait strictement suivant les modalit?s ?nonc?es dans l'avis publi? ?